Morning Stock Movers: Zoom, Robinhood Markets, BioNTech

The video discusses the financial performance of Zoom, highlighting its declining revenue growth rates and market reactions. It also covers potential SEC policy changes affecting Robinhood's business model, with implications for its stock. The biotech sector's response to CDC booster shot recommendations is examined, along with expectations for Crowdstrike's upcoming earnings report.

What was the revenue growth for Zoom in Q4?

• 191%

• 54%

• 369%

• 15%

What is the critical business model for Robin Hood that was discussed?

• Subscription model

• Payment for order flow

• Commission-based trading

• Advertising revenue

Which company's shares fell 7% due to potential regulatory changes?

• Robin Hood

• DocuSign

• Zoom

• Biontech

What was the CDC's recent recommendation related to?

• Travel restrictions

• Mask mandates

• Booster shots

• New vaccine development

Which company's earnings report is expected after the bell?

• Crowdstrike

• Robin Hood

• Biontech

• Zoom